Inherited Abnormalities of Fibrinogen Follow-up

Updated: Dec 06, 2018
  • Author: Suchitra S Acharya, MD, MBBS; Chief Editor: Cameron K Tebbi, MD  more...
  • Print
Follow-up

Further Outpatient Care

Ideally, individuals with afibrinogenemia and symptomatic dysfibrinogenemia should be monitored by a comprehensive bleeding disorder care team experienced in diagnosing and managing inherited bleeding disorders; team members should be associated with a hemophilia and inherited bleeding disorders treatment center. Special attention should be paid to providing prophylactic treatment to pregnant women with afibrinogenemia as early as possible, with therapy administered both during pregnancy and after delivery. [24]

In patients with afibrinogenemia and symptomatic dysfibrinogenemia, thrombosis risk is another consideration, and in many of these individuals, anticoagulants and fibrinogen need to be administered concurrently. [24]

Next:

Deterrence/Prevention

Individuals who may require plasma-derived coagulation factor concentrates should be immunized with the hepatitis A and hepatitis B vaccine.

Patients should avoid taking aspirin, ibuprofen, and other nonsteroidal anti-inflammatory drugs (NSAIDs), as well as other medications that affect platelet function.

Prophylactic therapy is needed for patients with recurrent bleeding episodes or CNS hemorrhage or during pregnancy to prevent miscarriage. Indeed, females of childbearing age with afibrinogenemia must be educated with regard to the condition's effect on pregnancy and childbirth and the necessity of prophylaxis with fibrinogen.

Previous
Next:

Patient Education

Patients and families should be provided with instruction and educational materials to enhance understanding of their coagulation disorder, improve their ability to recognize the symptoms and signs of bleeding and/or thrombosis, and to identify emergency situations.

Patients should know how to contact their treatment center for immediate treatment and where to go to receive emergency care.

Patients should wear a MedicAlert bracelet or carry other identification of their hemostatic disorder and recommended therapy.

Previous